| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T480 |
0-275 |
Sentence |
denotes |
Yang Yu et al. conducted in vivo experiments with XYPI, and discovered that it could significantly protect mice infected with Staphylococcus aureus and Streptococcus pneumoniae, and significantly inhibited citric acid-induced cough frequency in guinea pigs (Yu et al., 2009). |
| T481 |
276-438 |
Sentence |
denotes |
Using in vitro experiments, Lu Wang et al. studied the inhibitory effect of XYPI on inflammatory factors released by LPS-stimulated mouse mononuclear macrophages. |
| T482 |
439-571 |
Sentence |
denotes |
The results showed that XYPI significantly inhibited the release of inflammatory factors such as TNF-α and IL-6 (Wang et al., 2008). |
| T483 |
572-788 |
Sentence |
denotes |
Yinglan Nie et al. explored the mode of action of XYPI in the treatment of acute lung injury by observing its effect on cytokine content in bronchoalveolar lavage fluid (BALF) following LPS-induced acute lung injury. |
| T484 |
789-1034 |
Sentence |
denotes |
The results showed that XYPI could play an anti-inflammatory role by modulating the balance of pro-inflammatory/anti-inflammatory cytokines and prevent excess anti-inflammatory responses during the course of acute lung injury (Nie et al., 2012). |
| T485 |
1035-1135 |
Sentence |
denotes |
Qi Liu et al. observed antiviral activity of XYPI against human rhinovirus-induced mouse infections. |
| T486 |
1136-1296 |
Sentence |
denotes |
XYPI significantly reduced the virus titer in trachea-lung tissue homogenate of infected mice, effectively inhibiting proliferation of human rhinovirus in mice. |
| T487 |
1297-1487 |
Sentence |
denotes |
Respiratory lesions were alleviated in tested animals, survival rate was improved, there were few adverse reactions, and it was an efficient and safe drug against human rhinovirus infection. |
| T488 |
1488-1550 |
Sentence |
denotes |
Its specific mode of action, however, was unclear (Liu, 2015). |
